Washington Tries to Outcompete China, Lilly’s $1.9B Abbisko Bet, and Pfizer’s $43B Seagen Question – This Week in Biotech #106
HHS unveils a clinical trial reform blueprint as Lilly doubles down on Chinese discovery, Pfizer's lung cancer ADC fails, and US health spending hits $5.7 trillion (6/19-25).
Welcome back to This Week in Biotech by Biotech Blueprint, edition 106, covering biotech and pharma news from June 19 to June 25, 2026.
🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.
🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.
👥 If you haven’t already, please connect with me or follow me on LinkedIn.
VIDEO SUMMARY
THIS WEEK’S KEY TAKEAWAYS 🔑
You could watch the central tension of this week play out on a single day. On Monday, the Department of Health and Human Services published a blueprint called Operation TrialBlazer, designed to pull early stage drug research back onto US soil and close the roughly 18 month head start China holds in moving a molecule from discovery into the clinic. Two days later, Lilly committed up to $1.9 billion in a multi target discovery deal with Abbisko, a Shanghai-based biotech. Washington is trying to make US drug development faster while the money keeps flowing to the place that’s already fast.
What’s changed is that Washington has stopped trying to only wall China off and started trying to outcompete it. The 2024 Biosecure Act didn’t slow China’s rise and lawmakers know it. So the response this week was about making US development more attractive, not punishing companies for working with China. Operation TrialBlazer promises clearer FDA expectations before an investigational new drug filing, fewer redundant toxicology requirements, more flexible trial protocols, and a consultation pilot to speed institutional review. Scott Gottlieb, the former FDA commissioner, put it plainly: “the time and cost advantage can’t tilt so heavily against US-based trials or we’ll lose our edge.” The thing nobody wants to say out loud is that it already has tilted, and a blueprint isn’t going to rebuild a clinical trial ecosystem in a quarter.
The deals from this week tell you where speed actually lives right now. Lilly-Abbisko was the headline, but Ollin Biosciences raised $330 million to push a China-licensed challenger to Roche’s Vabysmo through Phase 3, and Serapha Bio launched on a China-sourced in vivo base-editing program. US and European pharma keep buying de-risked, fast moving chemistry from Chinese developers, while US policy scrambles to make domestic development competitive enough that the next generation of those molecules originates here instead. Both dynamics are running in parallel, and this week they were running right next to each other.
The other thread worth pulling on is Lilly itself, which appeared in three separate deals in five days: the $1.9 billion Abbisko pact, a $40 million equity check into AI design startup Absci, and a $50 million stalking horse bid for the platform assets of bankrupt Sangamo. Lilly is reconstructing its pipeline faster and more opportunistically than anyone else in the industry. Underneath all the deal flow is a quieter macro fact that’s worth holding onto: US health spending hit $5.7 trillion in 2025, up 7.3%, with GLP-1 demand explicitly named as a driver. The bill for the obesity revolution is now showing up in the national accounts, and that’s the backdrop everyone in this space has to operate against.
BIOTECH/PHARMA NEWS 🧬
Got it. Going to scrub the whole news section for AI tells: parallel constructions, abstract analytical narration, formulaic “X tried to Y. Z tries to Q” structures, dramatic short sentences, and stiff phrasing.
Biotech/Pharma News 🧬
🔹 HHS published a reform blueprint called Operation TrailBlazer on June 23 built around one competitive problem. A US drugmaker can take far longer than 18 months to move a molecule from discovery into a clinical trial, while China routinely does it inside that window. The proposed fixes are procedural but real. The FDA would specify required data before an IND filing to cut redundant toxicology and chemistry work, allow more flexible trial protocols to reduce amendment filings, and run a consultation pilot that lets developers engage research institutions during IND preparation. NIH would push telehealth, remote monitoring, real-world data, and AI to widen enrollment into rural and underserved areas. There’s even an examination of whether trial participant stipends beyond expense reimbursement are legal under anti kickback rules. The 2024 Biosecure Act tried to slow China down by restricting access. This blueprint takes the opposite approach and tries to make US drug development competitive enough that companies don’t need to look abroad. Whether it actually works depends on execution inside an FDA that has cycled through multiple commissioners and senior reviewers over the past few months, which is exactly the kind of capacity that procedural reform assumes is intact.
🔹 Lilly agreed on June 23 to pay Abbisko Therapeutics an undisclosed upfront plus up to $1.9B in milestones, with tiered royalties, for discovery and early development across multiple undisclosed targets. The deal builds on a 2022 small molecule collaboration between the two companies, so this is a continuation. The timing matters. Hours after the HHS blueprint announcement, the most acquisitive company in pharma chose to widen its bet on Chinese discovery chemistry instead of pulling work back to the US. Abbisko, based in Shanghai, runs the discovery and early development. Lilly holds the development and commercial economics. It’s the same licensing arbitrage model that BMS-Hengrui, Pfizer-Kailera, and Merck-Terns institutionalized over the past year, except now it carries added regulatory timing risk as lawmakers lay the groundwork for legislation that would mandate Treasury and Defense review of pharma deals with Chinese counterparts.
🔹 Novartis ran the domestic version of the same playbook on the same day, paying Antares Therapeutics $105M upfront and up to $1.8B in milestones, plus royalties, to generate small molecules against historically undruggable oncology targets. Antares is exactly the kind of US story Operation TrialBlazer is rooting for. It spun out of Scorpion Therapeutics in June 2025 with $177M in funding, after Scorpion sold a drug program to Lilly for up to $2.5B. Scorpion built its reputation by finding hidden binding pockets, including on PI3K-alpha, and Antares carries that toolkit forward. Its lead oncology program is expected to enter human testing in 2026. Put Novartis-Antares next to Lilly-Abbisko and you get the week’s competitive map in two transactions. Big pharma will pay roughly the same nine figure upfront and ten figure biobucks for fast discovery chemistry whether it sits in Boston or Shanghai.
🔹 Sangamo Therapeutics, one of the original zinc-finger gene-editing companies, filed for Chapter 11 in Delaware on June 23 and lined up initial buyers to anchor an auction of substantially all its assets. Lilly agreed to pay $50M plus assumed liabilities for Sangamo’s capsid delivery platform, zinc-finger platform, modular integrase platform, and its ST-506 prion disease program. Astellas separately agreed to $25M at closing plus up to $25M in milestones for the Fabry disease program ST-920. This is the gene therapy shakeout playing out as a fire sale. A foundational platform company that couldn’t fund itself through to commercial value, with its technology getting absorbed by deep pocketed buyers at distressed prices. For Lilly, $50M buys an entire delivery and integrase toolkit to feed its expanding genetic medicine ambitions, the kind of price only available when the seller is in bankruptcy court.
🔹 Lilly also led a $100M stock offering in Absci, buying $40M of equity. The 13.5M shares priced at $7.41, and Absci shares surged on the news alongside accompanying early clinical data. The money funds ABS-201, an AI-designed antibody being developed for both pattern hair loss and endometriosis. The asset’s selling point is durability. It showed a long lasting presence in the body, which could mean only a few injections per year, a meaningful convenience advantage in a cash pay aesthetic category. Initial proof of concept hair loss data are expected in the second half of 2026, with fuller results in early 2027. For Lilly this is a small optionality bet that checks two boxes the company clearly cares about, AI-driven drug design and a large consumer paid market, for the price of a rounding error.
🔹 US national health expenditure reached $5.7 trillion in 2025, a 7.3% increase and nearly $16,500 per person, according to figures published in Health Affairs on June 24. Government actuaries flagged hospital services and high priced prescription drugs, with GLP-1s explicitly named, and noted that utilization rather than unit price growth is what’s accelerating the trend. Spending is projected to top $6 trillion in 2026, with prescription drug outlays alone expected to exceed $560B next year, up 8.2% and growing faster than any other major category. The obesity drug boom is now showing up in the national accounts, not just in Lilly’s and Novo’s revenue lines. That shifts the political and payer conversation from whether these drugs work to who pays for what is becoming a permanent multi hundred billion dollar line item. The affordability constraint that has been building all year now has a federal number attached to it.
🔹 Pfizer’s sigvotatug vedotin, an integrin beta-6 targeting antibody-drug conjugate, failed its Phase 3 trial in second-line non-squamous non small cell lung cancer. The drug didn’t meaningfully extend overall survival versus docetaxel chemotherapy. Pfizer deferred specific numbers to a future medical meeting. The target was attractive on paper, since integrin beta-6 is expressed on roughly 90% of tumors, but a miss against standard chemotherapy is a miss. This is also a Seagen asset, and Pfizer has now absorbed about $4.5B in write offs tied to Seagen-acquired programs. The readout cuts deeper than one trial. It raises real questions about the return on Pfizer’s $43B Seagen acquisition. The drug’s surviving shot is a first-line combination with Keytruda, with data expected in 2027 in a different comparator and patient population. Early-line combinations sometimes rescue ADCs that have failed as monotherapy in later lines, but that’s a 2027 question now, not a 2026 one.
🔹 Two smaller deals reinforced the China-sourcing pattern this week. Ollin Biosciences raised $330M in a Series B to push a China-licensed challenger to Roche’s Vabysmo through Phase 3 in retinal disease. Vabysmo is one of Roche’s biggest growth products, used to treat wet age-related macular degeneration and diabetic macular edema, and brought in over $3B last year. Separately, Serapha Bio launched this week with a Series A focused on in vivo base-editing programs licensed from Chinese developers, building on the same lipid nanoparticle delivery approach Intellia validated in hereditary angioedema and Verve is extending in cardiovascular disease. Both companies are using the same playbook that defined this week. US capital plus Chinese discovery chemistry, pushed through Western regulatory and commercial channels. The launches don’t move the market on their own, but they show the licensing arbitrage model isn’t just happening at the large-cap level. It’s now the default starting position for new US biotech entrants too.
🔹 A more uncomfortable Lilly story closed out the week. Back in April, the FDA and Lilly granted compassionate-use access to retatrutide, the company’s not yet approved triple-G obesity drug, for a 79 year old patient with refractory obesity, obstructive sleep apnea, and pulmonary hypertension. The application was filed by a senior NIH clinician and drew interest from top health officials, which was unusual enough that Senator Maggie Hassan wrote to HHS Secretary Robert F. Kennedy Jr. asking whether the patient was President Trump or someone close to him. The White House said after publication that the application was not for the president. The patient’s identity is still unconfirmed. The compassionate-use pathway is meant for serious, immediately life threatening conditions, and the controversy is less about retatrutide itself than about whether access to experimental medicines runs through clinical need or political proximity. It’s a reputational footnote for the drug today, but a live question about how the FDA’s expanded-access discretion gets used.
Have a great rest of your week and thanks for reading Biotech Blueprint!
DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.
DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.
LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.
Image source: Alex Hogan/STAT